AstraZeneca Medical Missions for clinical practice change

For UK Healthcare Professionals only

AstraZeneca is a global pharmaceutical company with a major UK presence. Our purpose is to push the boundaries of science to deliver life-changing medicines that will positively transform the lives of patients.

Transforming clinical practice, in partnership with the NHS

Before the pandemic the NHS’s own Long Term Plan recognised the urgency of dealing with the growing burden of chronic diseases. This is even more critical at a time where unplanned admissions from such diseases take resource that could otherwise be used to clear the COVID backlog. Slowing or stopping disease progression through earlier patient diagnosis and proactive risk management would, in part, help to address this challenge by reducing the risk of hospitalisation and death.

We believe that we can support our NHS not only to recover from the pandemic but to “build back better”, partnering as the NHS and others did in the pandemic with a bold approach to innovative new ways of working. We want to work together to accelerate the early detection of chronic disease and ensure swift implementation of evidence-based care. Doing so will deliver for all patients and ensure a sustainable service worthy of national pride well into the future.

AstraZeneca’s medical mission for practice change outline our bold AMBITION to transform clinical practice for people living with chronic conditions: to reduce exacerbations, cardiovascular disease progression, hospital admissions & premature death. We’re targeting our Medical Mission work to areas of high need, tackling health inequalities that undermine the essence of the NHS.

AstraZeneca’s six medical missions for clinical practice change:

Zero tolerance for asthma attacks
All patients deserve access to anti-inflammatory medicines from the start

Eliminate Chronic Oral Corticosteroids (OCS) for asthma patients
Accelerate access to precision medicine, reduce OCS use by 90%

Early biology-based treatment of Chronic Obstructive Pulmonary Disease
Early diagnosis, treatment, prevention of decline, cardiovascular complications and premature death

Prevent onset of cardiorenal disease in Type 2 Diabetes
Treat beyond Haemoglobin A1C (HbA1c) to prevent onset of Heart Failure, Chronic Kidney Disease and premature death

Eradicate unplanned admissions for heart failure
Early diagnosis and treatment in the community, prevention of disease progression and hospitalisations

Reduce death and progression to End Stage Renal Disease (ESRD) in Chronic Kidney Disease
Early diagnosis and treatment, prevention of kidney function decline

For more information about AstraZeneca’s Medical Missions and partnering opportunities contact:

Binder Fagura
Head of UK external Scientific Engagement, Medical & Scientific Affairs, AstraZeneca UK Ltd